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Melatonin, a versatile molecule, is synthesized by the pineal gland but also by other organs, including
gastrointestinal tract, retina, thymus, bone marrow, and by leukocytes. Besides playing an important role in various
functions of the body, including sleep and circadian rhythm regulation, melatonin also shows immunoregulatory,
free radical scavenger and antioxidant functions. Because of these latter characteristics melatonin has also been
found to be effective in fighting viral infections in a variety of experimental animal and in vitro studies. These data
suggest a possible therapeutic potential of melatonin in human virus-induced disorders.
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Melatonin (N-acetyl-5-methoxytryptamine) is the major
neurohormone secreted by the pineal gland [1,2]. Initially,
it was reported as a skin lightening agent in amphibians
[3,4]. Further investigations showed that other functions
of the molecule were the regulation and reset of circadian
rhythms with involvement in the measurement of day
length, an environmental variable used for seasonal timing
of reproduction, metabolism and behavior in animal
species [5-7] (Figure 1). Acting virtually in every cell in
the organism, melatonin has been reported to possess
numerous additional functions, being involved in sleep
initiation, vasomotor control, anti-excitatory actions,
regulation of mitochondrial functions [8]. Melatonin
and its metabolites were found to have also important
immunomodulatory and antioxidant properties owing to
their direct and indirect antioxidant actions, i.e. by sca-
venging free radicals and by upregulating antioxidant
pathways [9-12].
Melatonin synthesis in the pineal gland and its
metabolism
In mammals, melatonin is synthesized in the pineal gland
with a rhythm regulated by an endogenous circadian
clock, the most important factor regulating its metabolism
being the light/dark cycle. Once formed, melatonin is im-
mediately released into the cerebrospinal fluid and in the* Correspondence: giovannirossi@ospedale-gaslini.ge.it
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distribution, and reproduction in any mediumblood, with a half-life in serum varying between less than
30 min to 60 min, and then metabolized in the liver and
in the kidney [13]. Melatonin exerts some of its actions
via binding to specific receptors and intracellular targets
[1,14]. There are two types of specific high affinity
membrane-associated melatonin receptors, MT1 and
MT2, able to trigger intracellular signaling by adenylate
cyclase or G-proteins [1,14]. A third membrane-associated
receptor, named MT3, has been described pharmacologi-
cally and characterized as the enzyme quinine reductase 2
[15]. This enzyme belongs to a group of reductases that
participate in the protection against oxidative stress by
preventing electron transfer reactions of quinines. High
affinity nuclear receptors to melatonin have also been
identified, belonging to the RZR/ROR nuclear hormone
receptor family [16]. Additional binding to intracellular
targets in the micromolar range, such as the enzymes
hydroquinone [17] and calmodulin [18] have been
reported, which mediate some of melatonin’s actions,
including protection of the cytoskeletal organization from
damage caused by free radicals [19]. In humans, melatonin
is secreted rhythmically with low levels during the daylight
hours and a peaks during darkness: in normal individuals,
blood concentrations begin to rise during the evening,
reaching maximum values between 02:00 and 04:00 am,
and then return to baseline levels during the late morning
[20]. Basal plasma melatonin levels may vary in several
physiological conditions: as an example, they are elevatedntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Figure 1 Main melatonin functions.
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return to “normal” levels soon after delivery [21].
Modulation of immune-inflammatory processes and
antioxidant activity
Besides being produced by the pineal gland, melatonin is
also synthesized by many other organs like gastrointestinal
tract, retina and leukocytes, both in the peripheral blood
and in the bone marrow [1,22]. As an example, human
lymphoid cells are an important physiological source
of melatonin since resting and phytohemagglutinin-
stimulated human lymphocytes synthesize and release
large amounts of melatonin, with the melatonin concen-
tration in the medium increasing up to five times the
nocturnal physiological levels in human serum [23]. Mela-
tonin produced by these non-endocrine organs is not
regulated by circadian cycles but rather respond to
other signals, exerting a paracrine or autocrine effect that
superimpose on the neuroendocrine hormone response
[23]. T-lymphocytes, natural killer (NK) cells, eosinophils,
and mast cells possess melatonin receptors [22]. Mela-
tonin has the capability to regulate leukocyte function
and contributes to the control of inflammation in tissues
acting as both an activator and inhibitor of the inflamma-
tory and immune responses [1,2,24,25]. Melatonin admi-
nistration increases the proliferative response of rat
lymphocytes, increases the number of NK cells, stimulates
the release of pro-inflammatory cytokines interleukin
(IL)-1 and tumor necrosis factor (TNF)-α, enhances
phagocytosis and modulates apoptosis [1]. On the con-
trary, in other experimental systems, melatonin inhibits
translocation of nuclear factor-kappa B (NF-kB) to the
nucleus, thereby reducing the upregulation of pro-
inflammatory cytokines [26]. In addition, melatonin is
able to prevent or reduce the inflammatory-derivedactivation of a variety of enzymes, including phospholi-
pase A2, lipoxygenase, and cyclooxygenases [1].
Melatonin is also a powerful antioxidant since it has
been reported to scavenge different types of free radicals
in vitro, in body fluids and in cells [1,27]. Indeed, the ac-
tivity and the expression of antioxidant enzymes such as
superoxide dismutase, glutathione, catalase, glutathione
peroxidase, and glutathione reductase have been shown
to be increased by melatonin, supporting its indirect
antioxidant action [1,27,28]. Further evidence of the
antioxidant effect of melatonin is provided by its ability
to reduce lipid peroxidation, a degradative phenomenon
involved in the pathogenesis of many diseases [10]. In
addition, melatonin can act on energy metabolism, stimu-
lating mitochondrial biogenesis, increasing the efficiency
of the electron transport chain in mitocondria, thereby
limiting electron leakage and free radical generation
[29,30]. Finally melatonin can increase mitochondrial
glutathione levels, leading to protection against free oxy-
gen species [31].
Protective effect of melatonin in experimental infections
due to encephalitis viruses
Because of its activity on the central nervous system
(CNS), associated with its capability to regulate immune
function and to act as powerful free-radical scavenger,
melatonin was thought to be able to play a protecting
role in infections induced by encephalitis viruses [32]. In
this context, melatonin was shown: a) to prevent paraly-
sis and death in mice infected with encephalomyocardi-
tis virus, a highly pathogenic and aggressive virus that
causes encephalitis, but also myocarditis, in rodents
[32,33]; b) to reduce viremia and significantly postpone
the onset of the disease and death in mice infected with
the lethal Semliki Forest virus, a classic encephalitis
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the mouse brain eventually leads to death [34]; c) to at-
tenuate noninvasive West Nile virus-induced disease,
counteracting the immunodepressive effect of stress ex-
posure, and to prevent the stress-related encephalitis
and death of the infected mice [34]; d) to decrease the
virus load in the brain and in serum of mice infected
with Venezuelan equine encephalomyelitis virus, redu-
cing mortality rates, delaying the onset of the disease
and deferring the time to death [35]. All these studies
suggest the concept that the protective mechanisms of
melatonin against infections due to encephalitis viruses
is probably due to a variety of functions, including the
antioxidant activity and the ability to regulate immune
functions inhibiting an excessive inflammatory response.
Protective effect of melatonin in respiratory syncytial
virus (RSV) infection
Results confirming the antioxidant activity of melatonin
were obtained in studies performed on the RSV infection
[36] (Figure 2). RSV is a common cause of bronchiolitis, a
severe lower respiratory tract disease that infects nearly all
infants by age three worldwide [36,37]. This disorder is
characterized by an extensive damage to the bronchial epi-
thelial cells and by massive infiltration and activation of
inflammatory cells into the airways with production of re-
active oxygen species [38]. Indeed, mice inoculated intrana-
sally with RSV showed elevation of oxidative stress due to
rises in nitric oxide (NO), hydroxyl radical (•OH) and
malondialdehyde (MDA), associated with an opposite de-
creases in glutathione (GSH) and superoxide dismutases
(SOD) activities. Pre-treatment of the animals with mela-
tonin resulted in marked reduction of acute lung oxidative
injury, with suppression of NO, •OH and MDA generation
and restoration of GSH and SOD levels in the lung [36]. In
RSV-infected mice, inhibition of oxidative stress was also
associated with a reduced production of proinflammatory
cytokines, such as TNF-α [36]. Although “physiologically
controlled” inflammation is required for virus clearance, ab-
errant and exaggerated inflammatory reaction during RSV
infection results in an extensive parenchymal damage withFigure 2 Melatonin in experimental Respiratory Syncytial Virus infectdevelopment of severe diseases, such as bronchiolitis and
pneumonia [37]. TNF-α is a prooxidant cytokine able to
amplify the host inflammatory response to respiratory viral
infections [38], stimulating the inducible NO synthase
(iNOS)-dependent NO production at transcriptional level,
at least partially through activation of the NF-kB-dependent
pathways [39]. In mice increased iNOS-derived NO pro-
duction after RSV infection contributes to both airway
inflammatory changes and airway dysfunction, while in-
hibition of NO synthesis significantly reduces pulmo-
nary inflammation and airway hyperresponsiveness [40].
Consistently, treatment of RSV-infected mice with an
antioxidant (butylated hydroxyanisole) induced a sig-
nificant reduction of RSV-induced pulmonary cytokine
production with inhibition of lung recruitment of inflam-
matory cells, especially neutrophils, which are the major
cell type responsible for oxidative burst in response to in-
fectious stimuli [41]. Production of proinflammatory and
prooxidant cytokines in response to RSV infection is in-
duced by recognition by toll-like receptors (TLR) of viral
double-stranded RNA, produced during viral replication.
The downstream signaling pathway from TLR leads to acti-
vation of interferon (IFN) regulatory factor-3 and/or NF-kB
and subsequent expression of numerous pro-inflammatory
factors. Interestingly, it has been shown that melatonin
decreases the TLR- mediated downstream gene expression
in RSV-infected macrophages and the subsequent NF-
kB-dependent gene expression, such as those encoding
for TNF-α and iNOS [42]. These results suggest that in
RSV infection melatonin may at least in part prevent the
injury to the airway structure through the inhibition of the
oxidative stress and of the production of proinflammatory
cytokine and therefore be a useful therapeutic agent in
RSV-induced pulmonary disease. Recent evidence suggests
that respiratory disorders induced by many other human
viral pathogens may result from exuberant generation of
reactive oxygen species by inflammatory cells in response
to infection [43]. Finally melatonin has been reported to
be effective in human studies performed on in infants with
disorder characterized by excessive inflammatory reaction
and oxidative damage, overwhelming the physiologic anti-ion.
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positive effects of melatonin treatment have been reported
in: a) newborns with sepsis, with reduction of serum levels
of lipid peroxidation products and with increased survival
[44]; b) in preterm infants with respiratory distress syn-
drome, reducing early serum indicators of chronic lung
disease, i.e. plasma concentrations of IL-6, IL-8, TNF-α
and of nitrite/nitrate [45]; c) in newborns with respiratory
distress syndrome, reducing the levels of proinflammatory
cytokines IL-6, IL-8, TNF-α in tracheobronchial aspirate
and improving the clinical outcome [46].
Conclusions
Modulation of the inflammatory response and of the re-
active oxygen species production and of the related oxi-
dative stress therefore represents a potential novel
pharmacological approach to ameliorate the host reac-
tions against viral infections and their long-term conse-
quences [47,48]. One possible weakness of melatonin is
its short half-life and the relatively low levels in serum
during day hours [11,14]. Administration of melatonin
to humans at pharmacological concentrations is essen-
tially non-toxic, also in the neonatal period [49] and the
results obtained in vitro and in experimental animals
support a possible beneficial immunoregulatory and
anti-oxidant role of this molecule in viral infection and
address its possible therapeutic potential in human
virus-induced diseases.
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